SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

Prior treatment

• Patient receives a kidney transplant from a living donor, or receives segmental pancreatic transplant, or a previous kidney transplant alone

Other illness

• Patient has a history of an extensive abdominal operation or a hernia in the abdominal wall
• Patient is allergic or intolerant to any drug comprising both immunosuppressive protocols
• Patient has malignancy or history of malignancy, with the exception of adequately treated localized squamous cell or basal cell carcinoma, without recurrence.
• Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication

Lab values

• Patient has a positive T-cell cross-match on the most recent serum specimen
• Patient is known for active liver disease or has significant liver disease; defined by ASAT and ALAT serum levels greater than 3 times the upper limit of normal

Age

• Donor is older than 65 years of age

Other

• Patient is pregnant or breastfeeding
• Patient has a high immunological risk, defined as a PRA grade > 50%

• 1 Male or female patients, of 18 to 65 years of age, with a pre- or an end-stage renal failure, Type 1-diabetic nephropathy
• Patient is scheduled to be put on waiting-list for a primary simultaneous pancreas/kidney (SPK) cadaver transplant